Navigation Links
Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
Date:11/13/2007

LAGUNA NIGUEL, Calif., Nov. 13 /PRNewswire/ -- Inspiration Biopharmaceuticals announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin clinical trials with IB1001, an intravenous recombinant Factor IX (rFIX) product for the on demand and prophylactic treatment of the bleeding disorder associated with hemophilia B.

Upon FDA approval of the IND application, Inspiration Biopharmaceuticals intends to enter Phase 1/2 clinical trials to evaluate the pharmacokinetics (PK) and safety profile of IB1001, compared with the commercially available Factor IX products; rFIX, BeneFix(R) and plasma-derived Factor, MonoNine(R). Following successful completion of the PK phase of this study, patients will then enroll in one of two trials: a six month Phase 1/2 On Demand trial to document safety and efficacy in treating spontaneous bleeding episodes or a pivotal Phase 2/3 Prophylaxis trial to document safety and efficacy in the prevention of spontaneous bleeding. In addition, the safety and efficacy of peri-surgical prophylactic administration of IB1001 to control bleeding during surgical procedures will be evaluated. The rate of inhibitor formation will be evaluated throughout all phases of the clinical investigation of IB1001.

"We are excited to be filing an IND for IB1001," said Michael Griffith, Ph.D., President and CEO, Inspiration Biopharmaceuticals. "Preclinical studies have demonstrated the expected PK and safety profile for IB1001 when compared to the clinically proven commercial Factor IX products. Our cost-effective manufacturing platform for Factor IX positions Inspiration to expand the global supply of i.v. rFIX and to develop next generation products to facilitate prophylactic care of the hemophilia B patients worldwide. Our ultimate goal is to leverage our low cost manufacturing technology to find the means for non-invasive delivery of Factor IX which we believe may represe
'/>"/>

SOURCE Inspiration Biopharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... MEETING, Pa. , Sept. 22, 2014 /PRNewswire/ ... announced today it has initiated a phase I ... trial will evaluate the safety, tolerability, and immunogenicity ... 6 (HPV-6), which causes most aerodigestive cancers. ... nose, throat, vocal cords, and parts of the ...
(Date:9/22/2014)... SAN DIEGO , Sept. 22, 2014 Arena ... the company is scheduled to present a corporate overview ... conference on Friday, September 26, 2014, at 11:30 a.m. ... Broadway Hotel in New York City ... presentation will be available under the investor relations section ...
(Date:9/22/2014)... Sept. 22, 2014 Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... has been appointed President and Chief Executive Officer, effective ... has stepped down from his executive and Board roles ... through the first quarter of 2016.  ...
Breaking Medicine Technology:Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 4Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 5
(Date:9/22/2014)... Angeles, CA (PRWEB) September 22, 2014 ... life insurance industry is now easier using the Quotes ... who are trying to local universal life insurance pricing ... The adult coverage plans that are easily viewed when ... that underwrite specific lengths of coverage. The plan data ...
(Date:9/22/2014)... Manhattan residents who suffer with hip ... hip , which could be bursitis now have a ... now offered at New York Dynamic Neuromuscular Rehabilitation Center. ... occurs when the trochanteric bursa becomes irritated or inflamed. ... between the iliotibial band and the greater trochanter. Most ...
(Date:9/22/2014)... seems futuristic, if not impossible. But with a ... researchers at University of California, San Diego School ... an entire, functional eye a reality. , "A ... for vision restoration," said Jeffrey Goldberg, MD, PhD, ... at University of Pittsburg Medical Center and Boston ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 This Flash ... on stakeholder management needs for the Prostate Cancer market. ... Experts on stakeholder strategies for any launching Prostate Cancer ... of differentiation within an increasingly crowded market , ... The impact of identifying community-based thought leaders and stakeholders ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 The ... the nation’s leading nonprofit authority on the use ... information exchange, announced findings from its recent industry ... Plan Identifier (HPID) within electronic transactions adopted under ... WEDI conducted the survey from August 20 to ...
Breaking Medicine News(10 mins):Health News:Universal Life Insurance Prices for Adults Added to National Insurer Portal Online 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:Looking ahead: Whole eye transplant under development 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3
... aiding joint inflammations in conditions like // arthritis. ... of the immune cells to secrete chemicals that will ... to arthritis. The enzyme cathepsin G attracts accumulation of ... tissue and cartilage in joints leading to the inflammatory ...
... a common water pollutant called arsenic may not be the ... a gene called CYT19 in people, particularly in children, that ... arsenic. ,Arsenic exposure had long been associated with health ... problems, and neurological disorders. It can enter the body through ...
... could run using a pollution free energy source.// ... working towards this solution to look at making hydrogen fuel ... hydrogen would reacts with oxygen to produce water and energy. ... would be pollution free. A similar mechanism is already followed ...
... had lead to inability to curbing of inflammatory cells// ... likewise. Researchers from Oregon Health & Science University have ... the low immune problem that leads to progress of ... disease of the central nervous system. There is no ...
... Prostate cancer is the commonest cancer effecting men. Benefits ... watermelon, papaya and pink grapefruit( most lycopene in processed ... known for sometime in preventing the aging process ... It is now being looked at for preventing and ...
... People suffering from diabetes type 1 or type 2 ... tract infections and skin infections. ,Some other ... kidney damage, nerve damage, eye problems that can lead ... a major risk factor for incidence of diabetes of ...
Cached Medicine News:Health News:Pollution Free Hydrogen based fuel for Energy 2Health News:Pollution Free Hydrogen based fuel for Energy 3
Designed to meet the requirements of reagent grade water for routine analysis....
... L/min of Type I ultrapure water, , ... Plus System is designed to provide the ... pretreated by reverse osmosis, distillation or deionization. ... quality which exceeds Type I ASTM/CAP/NCCLS specifications.,The ...
... Basic Laboratory Needs, Synergy systems produce ultrapure water ... 1 to 1.2 L/min to meet the basic ... incorporates a dual-wavelength UV lamp (185 nm and ... of organic contaminants (< 5 ppb TOC when ...
... Compact System Produces Type I Water Directly from ... designed for scientists who need 5 to 15 ... not have easy access to acceptable quality pretreated ... 0.6 L/min of ultrapure (Type I) water on ...
Medicine Products: